文献速递浆细胞疾病

每周一次卡非佐米联合来那度胺地塞米松治疗新诊断多发性骨髓瘤的1b期研究

A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
PubMed 文献 · Am J Hematol · 2020-12-15

该1b期研究评估每周一次卡非佐米联合来那度胺地塞米松(每周KRd)在新诊断多发性骨髓瘤(NDMM)患者中的安全性和活性。在20/56 mg/m²剂量扩展组(n=33)中,≥3级治疗 emergent 不良事件率为63.6%,4周期内总缓解率97.0%(≥VGPR 69.7%);中位随访8.1个月,中位无进展生存期未达到。

要点

  • 每周KRd(卡非佐米56 mg/m²)在NDMM中显示出可控的安全性和 promising 的活性。
  • 20/70 mg/m²剂量扩展组因严重不良事件暂停,最终采用20/56 mg/m²剂量。
  • 4周期内ORR达97.0%,≥VGPR率69.7%;未移植患者ORR 93.3%,≥VGPR 80.0%。

核心结论

  • 每周一次KRd(卡非佐米56 mg/m²)在新诊断多发性骨髓瘤中具有 favorable 的安全性特征和 promising 的活性。

研究设计与样本

  • 结果报告基于卡非佐米20/56 mg/m²剂量扩展组(n=33)。
  • 给药方案:卡非佐米第1、8、15天;来那度胺25 mg第1-21天;地塞米松40 mg于卡非佐米给药日(第1-8周期另加第22天),最多18个28天周期。

主要发现

  • ≥3级治疗 emergent 不良事件率为63.6%。
  • 25例患者进行干细胞采集,18例接受自体干细胞移植,5例移植后恢复研究中的KRd治疗。
  • 20/56 mg/m²队列基于第4周期最佳总缓解的ORR为97.0%(≥VGPR 69.7%)。
  • 未接受自体干细胞移植的患者(n=15)中位周期数16.0,ORR 93.3%(≥VGPR 80.0%)。
  • 中位随访8.1个月,中位无进展生存期未达到。

关键数值与推荐

  • 20/70 mg/m²剂量扩展组因严重不良事件暂停;经两步剂量递增评估剂量限制性毒性后,开放20/56 mg/m²剂量扩展组。

临床怎么用

  • 每周KRd(卡非佐米56 mg/m²)可作为新诊断多发性骨髓瘤的一种治疗选择,支持在该setting中使用。

局限性

  • 样本量较小(剂量扩展组n=33),随访时间较短(中位8.1个月),为1b期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Twice-weekly carfilzomib with lenalidomide-dexamethasone (Rd) is an effective regimen for newly diagnosed multiple myeloma (NDMM). Here we evaluated once-weekly carfilzomib with Rd (once-weekly KRd) in NDMM patients. The NDMM patients were enrolled regardless of transplant eligibility. Patients received carfilzomib on days 1, 8, and 15; lenalidomide 25 mg on days 1-21; and dexamethasone 40 mg on carfilzomib days (also day 22 for cycles 1-8) for ≤18, 28-day cycles. Enrollment initiated in a carfilzomib 20/70 mg/m2 (20 mg/m2 on cycle one, day 1; 70 mg/m2 thereafter) NDMM dose-expansion arm, which was suspended because of serious adverse events. After evaluation of dose-limiting toxicities in a two-step-up dose-evaluation cohort, an NDMM dose-expansion arm (carfilzomib 20/56 mg/m2 ) was opened. Fifty-one NDMM patients were enrolled in dose-finding and dose-expansion cohorts. Results are presented for the carfilzomib 56 mg/m2 NDMM dose-expansion arm (n = 33). The grade ≥ 3 treatment-emergent AE (TEAE) rate was 63.6%. Twenty-five patients underwent stem cell collection; 18 proceeded to auto stem cell transplant, and five resumed KRd on study after autoSCT. The overall response rate (ORR) based on best overall response by cycle four was 97.0% (≥very good partial response [VGPR], 69.7%) in the NDMM 20/56 mg/m2 cohort. In patients who did not receive autoSCT (n = 15), the median number of cycles was 16.0; ORR was 93.3% (≥VGPR, 80.0%). At a median follow-up of 8.1 months, median progression-free survival was not reached. Once-weekly KRd (carfilzomib 56 mg/m2 ) had a favorable safety profile and promising activity in NDMM, supporting the use of this regimen in this setting.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Alsina M, Landgren O, Raje N, et al. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. Am J Hematol. 2020. PMID: 33125764. doi:10.1002/ajh.26041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。